Glenmark to commercialize BeiGene’s oncology drugs in India
- May 22, 2024
- Posted by: OptimizeIAS Team
- Category: DPN Topics
No Comments
Glenmark to commercialize BeiGene’s oncology drugs in India
Sub: Science and tech
Sec: Health
Tags: Tislelizumab, Zanubrutinib
Context:
- Drugmaker Glenmark has entered into an exclusive marketing and distribution agreement with BeiGene to register and commercialize the latter’s oncology medicines Tislelizumab and Zanubrutinib in India.
More on news:
- Glenmark will be responsible for locally required development, registration and distribution providing access to BeiGene’s oncology medicines for cancer patients across India.
About the drugs:
Tislelizumab:
- Tislelizumab is a novel anti-programmed cell death protein 1 (PD-1) monoclonal antibody for the treatment of advanced or metastatic esophageal squamous cell carcinoma and broad development for the treatment of various types of cancers.
- Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1).
- It was engineered to have a nullified Fc portion, thus minimizing binding to FcγR on macrophages and limiting treatment resistance via antibody-dependent phagocytosis.
Zanubrutinib:
- Zanubrutinib is a BTK inhibitor approved for treatment of certain hematological malignancies, with results of several studies reinforcing its favorable efficacy and safety profile.
- Zanubrutinib is a chemotherapy drug used to treat certain types of B-cell cancers.
- These cancers affect B-lymphocytes, a type of white blood cell that helps you fight off infection.
- They occur when your body makes too many abnormal B-cells.